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Abstract
Metabolic reprogramming is considered hallmarks of cancer. Aerobic glycolysis in tumors cells has been well-known for
almost a century, but specific factors that regulate lactate generation and the effects of lactate in both cancer cells and stroma
are not yet well understood. In the present study using breast cancer cell lines, human primary cultures of breast tumors, and
immune deficient murine models, we demonstrate that the POU1F1 transcription factor is functionally and clinically related
to both metabolic reprogramming in breast cancer cells and fibroblasts activation. Mechanistically, we demonstrate that
POU1F1 transcriptionally regulates the lactate dehydrogenase A (LDHA) gene. LDHA catalyzes pyruvate into lactate
instead of leading into the tricarboxylic acid cycle. Lactate increases breast cancer cell proliferation, migration, and invasion.
In addition, it activates normal-associated fibroblasts (NAFs) into cancer-associated fibroblasts (CAFs). Conversely, LDHA
knockdown in breast cancer cells that overexpress POU1F1 decreases tumor volume and [18F]FDG uptake in tumor
xenografts of mice. Clinically, POU1F1 and LDHA expression correlate with relapse- and metastasis-free survival. Our data
indicate that POU1F1 induces a metabolic reprogramming through LDHA regulation in human breast tumor cells, modifying
the phenotype of both cancer cells and fibroblasts to promote cancer progression.
Introduction
Cellular metabolism reprogramming is a hallmark of cancer
cells [1, 2]. Metabolic plasticity includes aerobic glycolysis,
also called the Warburg effect, a well-known feature of
tumors early recognized by Otto Warburg [3]. The
glycolysis occurring in cancer cells gives rise to a high-rate
glucose uptake and the conversion of pyruvate into lactate,
instead of converting into Acetyl CoA and leading to the
tricarboxylic acid (TCA) cycle and mitochondrial oxidative
phosphorylation (OXPHOS). Moreover, the lactate output
to the extracellular space results in acidification of tumor
microenvironment (TME) [4–6]. In addition to the key role
of lactate in tumor cell maintenance [7, 8], lactate is known
to affect stromal cells in the TME. For example, in immune
cells, lactate induces M2-like polarization of tumor-
associated macrophages (TAM) and TAM-induced
* Román Perez-Fernandez
roman.perez.fernandez@usc.es
1 Department of Physiology-Center for Research in Molecular
Medicine and Chronic Diseases (CIMUS), University of Santiago
de Compostela, Santiago de Compostela, Spain
2 Research Unit, Hospital Fundación de Jove, Gijón, Spain
3 Department of Obstetrics and Gynecology, Health Research
Institute of Santiago de Compostela (IDIS)-University of Santiago
de Compostela, Santiago de Compostela, Spain
4 Department of Radiation Oncology, Health Research Institute of
Santiago de Compostela (IDIS)-University of Santiago de
Compostela, Santiago de Compostela, Spain
5 Department of Morphological Sciences, Health Research Institute
of Santiago de Compostela (IDIS)-University of Santiago de
Compostela, Santiago de Compostela, Spain
6 Molecular Imaging Group. Department of Psychiatry, Radiology,
Public Health, Nursing and Medicine, and Health Research
Institute of Santiago de Compostela (IDIS). University of Santiago
de Compostela, Santiago de Compostela, Spain
7 Present address: Department of Pathology and Laboratory
Medicine, Weill Cornell Medicine, New York, NY, USA
Supplementary information The online version contains
















angiogenesis [9]. It also impairs T and natural killer cell
activation and compromises dendritic cell differentiation and
maturation that suppresses anticancer immune responses
[10, 11]. In endothelial cells, lactate has been demonstrated
to increase angiogenesis [12]. However, the role of lactate
on other stromal cell populations has not yet been fully
elucidated. For example, administration of exogenous lactate
in breast cancer cells has been shown to induce the cancer
stem cell (CSC) phenotype [13], but it is not clear which
source of lactate could contribute to inducing stemness: the
cancer cell-derived lactate, the CSC-produced lactate, or
both. Regarding fibroblasts, cancer cells reprogram the sur-
rounding fibroblasts to induce aerobic glycolysis. In turn,
fibroblasts produce lactate that can be taken up by cancer
cells and oxidized in the mitochondria for energy production
and tumor progression. This metabolic coupling is referred
to as the “reverse Warburg effect” [14]. In addition, a recent
study indicated that lactate secreted by pancreatic ductal
adenocarcinoma cells reprogram mesenchymal stem cells
epigenetically to differentiate into cancer-associated fibro-
blasts (CAFs), thus leading to tumor progression [15].
Lactate dehydrogenase A (LDHA) is the key enzyme
generating lactate from pyruvate. HIF-1, c-Myc, and p53 are
likely the most widely studied lactate regulators. Upregula-
tion of HIF-1 and c-Myc and suppression of p53 are
responsible for the metabolic switch to glycolysis in cancer
cells [16]. LDHA overexpression promotes cell proliferation
and invasion in pituitary adenomas [17], whereas reduction
in LDHA activity compromises the ability of tumor cells to
proliferate under hypoxia and severely diminishes tumor-
igenicity and tumor cell maintenance [7].
Transcriptional regulation of prolactin (PRL) and growth
hormone (GH) in the pituitary gland by the POU1F1 tran-
scription factor is well known [18, 19]. However, POU1F1
is also expressed in non-pituitary tissues, such as human
breast, where it also regulates GH and PRL [20, 21]. High
POU1F1 levels in breast cancer cells induce cell prolifera-
tion, reduce apoptosis, and increase migration and invasion
[22]. In fact, high expression of POU1F1 in breast cancer
correlates with poor clinical outcome [23]. Hypomethyla-
tion profiles in clusters of circulating breast cancer cells
have recently been identified in binding sites for several
transcription factors related to stemness and proliferation,
including POU1F1. This epigenetic mechanism has been
related to metastasis seeding [24].
The current study analyzes the role of POU1F1 in breast
cancer cell metabolism. Human breast cancer cell lines and
primary human breast tumors were used to evaluate the
effect of POU1F1 overexpression and POU1F1 knockdown
in the glycolysis pathway. Using immunodeficient mice, we
studied how cancer cells with POU1F1 overexpression and
LDHA blockade could affect tumor growth and glucose
uptake. In patients, POU1F1 and LDHA mRNA expression
was correlated with breast cancer clinical outcome. Finally,
in primary cultures of human breast tumors, we studied the
effect of both POU1F1 and LDHA on fibroblast activation.
Results
POU1F1 in breast cancer cells induces metabolic
reprogramming
Bioinformatic analyses of human breast cancer datasets
were carried out for glycolytic activity and other processes
related with proliferation and metabolism (Fig. 1A–C).
Glycolytic activity was found to be higher in breast tumors
than in normal breast (GSE109169), in triple-negative
breast cancer (TNBC) than in luminal A tumors
(GSE45827), and in bone metastasis than in primary tumors
(GSE103357). Interestingly, glycolytic activity was also
found to be higher in the breast cancer subtypes Luminal B
and HER2 as compared to luminal A (Supplementary Fig.
S1A–B). Given that POU1F1 is related to pituitary gland
development and cancer progression, we analyzed these
biological processes in the context of breast cancer. We
carried out an unbiased transcriptomic analysis by per-
forming a microarray (GSE64101) in the control luminal A
subtype of MCF7 cells with low endogenous POU1F1
expression (MCF7) and after transient transfection by a
POU1F1 overexpression vector (MCF7-POU1F1). To ana-
lyze these data, a gene-set enrichment analyses was per-
formed. We found that POU1F1 overexpression induced a
clear enrichment of glycolysis signature (NES= 2.01, P <
0.001) (Fig. 1D). Next, we selected well-known enzymes
and carriers involved in the glycolytic pathway (Fig. 1E)
and a real-time PCR was carried out before and after
POU1F1 overexpression. Our data confirmed significant
upregulation in mRNA expression of eight glycolysis-
related genes: HK2 (hexokinase 2), GAPDH (glycer-
aldehyde 3-phosphate dehydrogenase), PGK1 (phos-
phoglycerate kinase 1), PGAM1 (phosphoglycerate mutase),
ENO1 (enolase 1), ENO2, PKM2 (pyruvate kinase M2), and
LDHA (lactate dehydrogenase A). Downregulation of PFK1
(6-phosphofructokinase) and no changes of GPI (glucose-6-
phosphate isomerase), or ALDOA (aldolase A) glycolysis-
related genes (Fig. 1F) were observed. In addition, two key
transporters in glucose metabolism, SLC2A1 (glucose
transporter 1, GLUT1), and SLC2A4 (GLUT4), significantly
decreased and increased, respectively, after POU1F1 over-
expression. The mRNA expression of SLC16A3 (mono-
carboxylate transporter 4, MCT4), which is responsible for
transporting lactate out of cells, also significantly increased
after POU1F1 overexpression (Fig. 1F). Furthermore, the
C12orf5 gene which codes for the TP53-inducible glyco-
lysis and apoptosis regulator (TIGAR) protein, a well-
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known glycolysis p53-mediator [25, 26], decreases after
POU1F1 overexpression, and this could suggest a possible
role for TIGAR in POU1F1-induced glycolysis. To analyze
possible changes in secreted metabolites, conditioned
medium (CM) from MCF7 and MCF7-POU1F1 cells after
24 h of culture was analyzed by 1H-NMR assay (Supple-
mentary Fig. S2, A-B, and Supplementary Table S1).
Glycolytic- and TCA-derived metabolites showed dramatic
changes after POU1F1 overexpression, with a significant
decrease in glucose and a significant increase in lactate
(both P < 0.001) (Fig. 1G). Several TCA-derived metabo-
lites also presented significantly reduced levels in CM-
MCF7-POU1F1 cells (Fig. 1G). Altogether, our data indi-
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pyruvate to lactate production increased, while pyruvate to
TCA-cycle products decreased at least at the extracellular
level. To confirm the functional relevance of our findings,
glycolytic activity of breast cancer cells was assayed by
measuring extracellular acidification rate (ECAR), quanti-
fication of basal glycolysis, compensatory glycolysis, and
mitochondrial oxygen consumption rate (OCR)/proton
extrusion rate (glycoPER) basal ratio in both MCF7 and
MCF7-POU1F1 cells. The data obtained show that
POU1F1 significantly increased the glycolytic profile as
compared to control MCF7 cells (Fig. 2A, B). Conversely,
knockout of POU1F1 (MDAsgPOU1F1) using the CRISPR
methodology in the MDA-MB-231 cell line (triple-negative
subtype, with high endogenous levels of POU1F1) pre-
sented a significant decrease in the glycolytic profile com-
pared to control cells (MDAsgC) (Fig. 2C, D and
Supplementary Fig. S3). Primary cultures of two human
breast tumors with low POU1F1 protein expression (PDT 1)
and high expression (PDT 6) (see below) were selected for
glycolytic activity analyses. As shown in Fig. 2E, F, similar
data were obtained for the human breast tumors and the
breast cancer cell lines, which strongly suggests that
POU1F1 regulates the glycolysis pathway in breast tumors.
POU1F1 regulates LDHA expression in breast cancer
LDHA is a key enzyme in the glycolysis pathway, trans-
forming pyruvate into lactate. Aberrantly high expression of
LDHA has been demonstrated in multiple cancers,
including breast cancer, and it has been associated with
malignant tumor progression. In fact, bioinformatic search
of human breast cancer tumors and normal breast samples
(GSE22820) revealed a significant (P < 0.001) increase of
LDHA mRNA expression in human breast tumors as com-
pared with normal mammary tissue (Fig. 3A). Using the
same database, we also classified breast tumors and normal
samples according to POU1F1 mRNA expression (Fig.
3B). Further analyses also showed a significant (P < 0.05)
correlation between POU1F1 and LDHA mRNA expression
(Fig. 3C, D).
In order to evaluate the hypothesis that POU1F1 could
regulate the LDHA gene at transcriptional level, we sear-
ched for potential binding sites of POU1F1 in the LDHA
promoter using the JASPAR database (http://jaspar.genereg.
net/), and found two putative motifs for POU1F1 in the
LDHA gene promoter region (Fig. 3E). These two con-
sensus elements for POU1F1 were located at −76 to −62
bp upstream and +276 to +290 bp downstream from the
start transcription site in the LDHA promoter (Fig. 3F). To
evaluate the possible transcriptional regulation of LDHA by
POU1F1, a luciferase reporter assay in the absence or pre-
sence of POU1F1 was carried out using three plasmids: (a)
the wild LDHA promoter (LDHApromoter-WT, −101 to
+315 bp), (b) a plasmid with deletion of the first POU1F1
binding site (LDHApromoter-DEL1, deletion of −76 to −62
bp), and (c) a plasmid with deletion of the second POU1F1
binding site (LDHApromoter-DEL2, deletion of +276 to
+290 bp). HEK 293 cells co-transfected with the LDHA-
promoter-WT and the POU1F1 overexpression vector sig-
nificantly increased luciferase activity as compared with
control (P < 0.01), whereas deletion of both the first and the
second POU1F1 binding sites significantly reduced luci-
ferase activity (P < 0.01 and P < 0.001) (Fig. 3G). In fact,
interrogation of the epigenetic status of LDHA gene pro-
moter in breast cancer cell lines showed a peak enrichment
in H3K27ac, an epigenetic mark associated with higher
activation of transcription (Fig. 3H). Furthermore, transient
POU1F1 overexpression in MCF7 cells significantly (P <
0.001) increased LDHA mRNA expression (Fig. 3I). Wes-
tern blots also indicated a visible increase in LDHA protein
expression after POU1F1 overexpression in both transient
(Fig. 3J) and stable (Supplementary Fig. S4A) MCF7 cells.
Conversely, transient knockdown of POU1F1 using a
pLKO-shPOU1F1 vector in MDA-MB-231 cells sig-
nificantly decreased LDHA mRNA (P < 0.001, Fig. 3K) and
protein (Fig. 3L) levels. Confocal microscopy of MCF7
control cells transfected stably with the pTRE2 control
vector (MCF7), MCF7 cells transfected stably with the
pTRE2-POU1F1 vector (MCF7-POU1F1), MDA-MB-231
control cells transfected with the pLentiCRISPRv2 control
(MDAsgC), and after POU1F1 knockout (MDAsg-
POU1F1), indicated a correlation between POU1F1 (in red)
Fig. 1 POU1F1 induces metabolic reprogramming in human
breast adenocarcinoma cells. A–C Dataset enrichment graphs related
with metabolic and proliferation process categories from Hallmark
collection (up) and GSEA plot of enrichment in Glycolysis geneset
(down). Gene expression data obtained from GSE109169, GSE45827,
and GSE103357 as indicated: A Tumor breast cancer patient samples
(n= 25) vs normal breast (n= 25); B TNBC breast tumors (n= 41) vs
Luminal A breast tumors (n= 29); C Breast cell line derived from
bone metastasis patient (n= 3) vs primary tumor cells (n= 2). FDR
false discovery rate, NES normalized enrichment score. D Dataset
enrichment graphs related with metabolic, proliferation, and develop-
ment process categories from Hallmark collection (left) and GSEA plot
of enrichment in Glycolysis geneset (right) of microarray data from
POU1F1-overexpressing MCF7 cells vs MCF7 cells (GSE64101). E
Glycolysis pathway and catalytic enzymes (in red). F qPCR of gly-
colytic enzymes, carriers, and factors involved in the glycolytic
pathway in control and POU1F1-overexpressing MCF7 cells.
POU1F1, HK2 (hexokinase 2), GPI (glucose-6-phosphate isomerase),
PFK1 (6-phosphofructokinase), ALDOA (aldolase A), GAPDH (gly-
ceraldehyde 3-phosphate dehydrogenase), PGK1 (phosphoglycerate
kinase 1), PGAM1 (phosphoglycerate mutase), ENO1 (enolase 1),
ENO2, PKM2 (pyruvate kinase M2), LDHA (lactate dehydrogenase
A), SLC2A1 (glucose transporter 1, GLUT1), SLC2A4 (GLUT4),
SLC16A3 (monocarboxylate transporter 4, MCT4), and C12orf5
(TIGAR). G 1H-NMR assay of glycolytic- and TCA-derived meta-
bolites in conditioned medium (CM) of MCF7 and MCF7-POU1F1
cells after 24 h culture. *FDR-adjusted p value (q-value) < 0.05; **<
0.01; ***0.001; ns not significant.
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and LDHA (in green) immunodetection (Fig. 3M). Sup-
plementary Fig. S4B also shows a decrease in LDHA pro-
tein expression after knockout of POU1F1 in MDA-MB-
231 cells using three different CRISPR clones.
POU1F1-induced lactate facilitates cancer
progression in breast cancer cells
To evaluate the effect of lactate on breast cancer cells,
glycolytic activity (ECAR and basal glycolysis) was
assayed in stable MCF7 overexpressing POU1F1 cells
before and after treatment with either a pharmacological
LDHA inhibitor (GSK2837808A, referred as LDHAi,
10 μM for 24 h) or after genetic LDHA knockdown
(shLDHA, Supplementary Fig. S4C). Figure 4A, B indicate
a significant decrease in ECAR and basal glycolysis in
MCF7-POU1F1 cells after both LDHA procedures. Pre-
vious studies have shown an LDHA-dependence on cancer
cell proliferation under hypoxic environment conditions
[27]. Our data are in line with these reports. Proliferation of
MCF7 cells significantly increased after POU1F1 over-
expression in both normoxic and hypoxic cultures, as we
previously demonstrated [28], but only under hypoxia does
the treatment of MCF7-POU1F1 cells with the LDHAi and
knockdown of LDHA significantly (P < 0.05) reduce cell
proliferation (Fig. 4C, D). Next, migration of MCF7-
POU1F1 cells was evaluated using a trans-well assay. A
significant increase in cell migration was observed in MCF7
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Fig. 2 POU1F1 regulates the glycolytic profile of breast cancer cell
lines and primary tumors in vitro. A Representative ECAR Gly-
colytic Rate Assay profile in MCF7 and MCF7-POU1F1 cells. cs cells.
B Quantification of basal glycolysis, compensatory glycolysis and
mitoOCR/glycoPER basal ratio in MCF7 and MCF7-POU1F1 cells. C
Representative ECAR Glycolytic Rate Assay profile in control
(MDAsgC) and POU1F1-knocked-out MDA-MB-231 (MDAsg-
POU1F1) cells. D Quantification of basal glycolysis, compensatory
glycolysis and mitoOCR/glycoPER basal ratio in MDAsgC and
MDAsgPOU1F1 cells. E Representative ECAR Glycolytic Rate Assay
profile in human primary breast tumor-derived cultures (see Fig. 6D)
with low POU1F1 expression (PDT 1) and high POU1F1 expression
(PDT 6). F Quantification of basal glycolysis, compensatory glyco-
lysis and mitoOCR/glycoPER basal ratio in PDT 1 and PDT 6. Data
are expressed as mean ± SEM. *P < 0.05, **P < 0.01, and ***P <
0.001.
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cells after POU1F1 overexpression as compared with con-
trol cells (Fig. 4E). However, treatment either with LDHAi
(P < 0.001) or shLDHA (P < 0.01) significantly reduced cell
migration (Fig. 4E). Finally, to analyze cancer cell invasion,
we carried out organotypic cultures using control MCF7-
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LDHAi or transfected with shLDHA. Our data indicate a
significant decrease (P < 0.05) in cell invasion after both
experimental manipulations (Fig. 4F). In summary, our data
suggest that either blocking LDHA enzymatic activity or
decreasing LDHA expression in MCF7-POU1F1 cells
reduces proliferation, migration, and invasion of breast
cancer cells.
POU1F1-regulated LDHA influences tumor growth
and tumor glucose uptake in vivo, and both POU1F1
and LDHA expression are related to clinical outcome
To evaluate in vivo the effect of LDHA knockdown in
POU1F1-overexpressing cells, immunodeficient BALB/c-
nu mice were injected with control MCF7 cells (stably
transfected with the pTRE2 control vector, n= 7, MCF7),
MCF7 cells with POU1F1 overexpression (pTRE2-
POU1F1-overexpressing vector plus the pLKO control
vector, n= 7, MCF7-POU1F1), and with MCF7 cells with
POU1F1 overexpression and LDHA knockdown (pTRE2-
POU1F1-overexpressing vector plus the pLKO-shLDHA
plasmid, n= 7, MCF7-POU1F1-shLDHA). Xenografted
tumors were monitored every 3 days, and mice were
sacrificed at day 15 post injection. Body weight remained
stable among all three groups (Fig. 5A). Tumor volume in
MCF7-injected mice was negligible at day 15, but a con-
tinuous growth of tumor volume in both the MCF7-
POU1F1 and the MCF7-POU1F1-shLDHA groups was
observed during the study, being significatively higher at 9,
12, and 15 days in MCF7-POU1F1 mice comparing to
LDHA knocked-down mice (Fig. 5B). POU1F1 and LDHA
protein levels in three tumors from each group were assayed
by western blot showing, as expected, reduced levels of
LDHA in MCF7-POU1F1-shLDHA-injected mice with
respect to MCF7-POU1F1 group (Fig. 5C). Immunohis-
tochemistry analyses of tumor xenografts showed high cell
proliferation (ki67 marker) in both MCF7-POU1F1 and
MCF7-POU1F1-shLDHA groups with respect to MCF7-
injected group, but ki67 staining was reduced in MCF7-
POU1F1-shLDHA as compared to the MCF7-POU1F1
injected mice (Fig. 5D).
In addition, four mice per group were assayed for glu-
cose uptake just before being sacrificed, using [18F]FDG
PET/CT scans. SUVmax indicates a significant (P < 0.01)
increase in glucose uptake in tumors from MCF7-POU1F1
injected mice as compared to control group (Fig. 5E).
However, tumors in mice injected with MCF7-POU1F1-
shLDHA cells had significantly reduced SUVmax (P < 0.05)
as compared with MCF7-POU1F1 injected mice, but
similar values to those found in control mice (Fig. 5E).
Finally, to study the possible relationship between
POU1F1/LDHA expression and clinical outcome, POU1F1
and LDHA mRNA was analyzed in a dataset of human
breast cancer patients. We found a significant correlation
between POU1F1/LDHA expression and both relapse-free
survival (RFS) (P < 0.001) and overall survival (OS) (P <
0.001) (Fig. 5F, G, and Supplementary Fig. S5).
POU1F1 expression in breast cancer tumor samples
correlates with CAF activation
Once we demonstrated that POU1F1 regulates LDHA and
that pharmacological or genetic manipulation of LDHA
induces phenotypic changes in breast cancer cells that
modify cancer progression, we studied whether POU1F1
could have an impact on TME, specifically on fibroblasts.
Numerous studies have shown increased NAF to CAF
activation in breast cancer [29]. To study the role of
POU1F1 in CAF activation, we first evaluated POU1F1
mRNA expression in 21 human breast tumors (Supple-
mentary Table S2). Tumor samples were classified as high
POU1F1 (POU1F1 higher than 75th percentile, n= 6) and
low POU1F1 (with levels below 25th percentile, n= 5)
mRNA expression (Fig. 6A). Based on this classification,
actin alpha 2 smooth muscle mRNA (ACTA2) expression
was evaluated as a key marker of CAFs. We found a sig-
nificant (R= 0.597, P= 0.0043) correlation between
POU1F1 and ACTA2 mRNA (Fig. 6B, C). POU1F1 and
Fig. 3 POU1F1 regulates LDHA expression. A Dispersion plot of
LDHA mRNA levels in human breast tumors (n= 176) and normal
tissues (n= 10) (GSE22820). B, C POU1F1 and LDHA mRNA levels
according to POU1F1 mRNA levels (high POU1F1: higher than 75th
percentile, and lower POU1F1: with levels below 25th percentile). D
Spearman correlation analysis of POU1F1 and LDHA mRNA
expression (log2) (n= 186). E, F JASPAR analysis indicates two
POU1F1 binding sites in the LDHA gene at positions −76/−62 bp and
+276/+290 bp with respect to transcription start site. DEL1 and DEL2
indicate deletion of POU1F1 binding sites. G The wild LDHA pro-
moter (−101 to +315 bp from the transcription start site; LDHApro-
moter-WT) and the LDHA promoter with specific deletions at the
POU1F1 binding sites (LDHApromoter-DEL1 and LDHApromoter-DEL2)
were subcloned into the pRP vector, transfected in HEK 293 cells, and
co-transfected with the control (pDream) or the pDream-POU1F1
overexpression vector for 48 h, and luciferase activity was measured.
Normalized relative luciferase units (RLU) were calculated as the ratio
of luciferase activity in control and POU1F1-transfected cells. H
H3K27Ac occupancy of LDHA promoter in human breast cancer cell
lines (GSE69112), analyzed by ChIPseq (MCF7, ZR75 and T47D:
Luminal A; CAL51, SUM159, and MDA-MB-231: Triple Negative
Breast Cancer). I MCF7 cells were transiently transfected with the
pDream-POU1F1 overexpression vector and 72 h later a qPCR was
carried out to evaluate LDHA and POU1F1 mRNA expression. J
Western blot of LDHA, POU1F1, and β-actin in MCF7 cells after
transient POU1F1 overexpression (n= 2). K LDHA mRNA in MDA-
MB-231 cells after POU1F1 knockdown for 72 h. L WB of POU1F1,
LDHA, and β-actin in MDA-MB-231 cells after POU1F1 knockdown
(n= 2). M Representative images of POU1F1 and LDHA after con-
focal microscopy in MCF7 and MDA-MB-231 cells after stable
POU1F1 overexpression (MCF7-POU1F1) and POU1F1 knockout
(MDAsgPOU1F1). DAPI was used as nuclei marker. Scale bar: 15 μm.
Data are expressed as mean ± SEM. **P < 0.01, and ***P < 0.001.
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ACTA2 protein (α-SMA) expression were also evaluated in
seven primary cultures of human breast tumors
(Supplementary Table S3). Both western blot and immu-
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Fig. 4 POU1F1-induced lactate acts on cancer cells to induce
cancer progression. A, B Administration of a LDHA inhibitor
(10 μM, GSK2837808A, referred as LDHAi) or LDHA knockdown
(shLDHA) in MCF7-POU1F1 cells for 24 h significantly decreases
extracellular acidification rate (ECAR) and basal glycolysis. Data were
obtained using an XFp seahorse cell analyzer. C, D Cell proliferation
in control and POU1F1-overexpressing MCF7 cells treated with
10 μM LDHAi or transfected with the pKLO-shLDHA vector for 72 h
under normoxic and hypoxic (1% O2) atmosphere. E Representative
figure and quantitative analysis of trans-well migration assays in
control cells (MCF7), POU1F1-overexpressing cells (MCF7-
POU1F1), and MCF7-POU1F1 cells either treated with LDHAi (upper
panel) or after LDHA knockdown (shLDHA, bottom panel). Scale bar:
100 μm. F Representative images of H&E-stained sections of MCF7-
POU1F1 cells cultured in an organotypic system in the presence of a
pharmacological LDHA inhibitor (LDHAi) or LDHA knockdown
(shLDHA), and quantification of cell invasion. Data are expressed as
mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar: 50 μm.
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between POU1F1 and α-SMA protein expression (Fig.
6D–F). Immunohistochemistry shows a representative
example of POU1F1 and α-SMA immunodetection in two
of the above-mentioned human breast tumors with high
(Fig. 6E) and low (Fig. 6F) POU1F1 protein levels. As
noted, POU1F1 is expressed at nuclear level in cancer cells,
whereas α-SMA immunoreactivity in CAFs is present at
cytoplasmic level. In line with the results at the mRNA
level, a significant (R= 0.764, P= 0.045) correlation
between POU1F1 and α-SMA protein expression was found
(Fig. 6G). Indeed, a significant (P= 0.048, HR= 1.13
(1–1.28)) relationship between POU1F1/ACTA2 mRNA
levels and RFS was found in a human breast cancer dataset
(n= 3951 samples) (Fig. 6H), which suggests a clinical
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To further evaluate the role of POU1F1 in NAF to CAF
activation, we selected three human primary breast tumors:
035, 823, and 2920 (Supplementary Table S4). NAFs were
obtained at least 2 cm away from the tumor. After tissue
culture, both NAFs and CAFs were isolated and carefully
characterized. Consistent with previous reports, fibroblasts
were classified according to ACTA2/α-SMA mRNA/protein
expression (NAFs have low ACTA2/α-SMA, and CAFs
have high ACTA2/α-SMA) (Fig. 6I–N). In addition, other
NAFs/CAFs markers, such as vimentin (VIM), fibroblast
activation protein (FAP), vascular endothelial growth factor
(VEGF), and C-X-C motif chemokine 12 (CXCL12) were
evaluated, showing a significant increase in VIM, FAP,
VEGF, and CXCL12 mRNA in CAFs with respect to NAFs
(Supplementary Fig. S6A–C). MCF7 cells with and without
POU1F1 overexpression were cultured for 24 h and CM
from either MCF7 or MCF7-POU1F1 cultures was added to
NAFs obtained from patient 823 (NAF823) to evaluate a
possible NAF to CAF activation (Fig. 7A). Overexpression
of POU1F1 (Fig. 7B) increased α-SMA protein levels in
NAF823 (Fig. 7C), and conversely, treatment of NAFs with
CM of MDA-MB-231 cells after knockout of POU1F1 (Fig.
7D, E) decreased α-SMA protein expression with respect to
NAFs treated with CM-MDA-MB-231 control cells (Fig.
7F). Two similar experiments—treatment with CM from
MCF7 cells before and after POU1F1 overexpression, and
treatment with CM from MDA-MB-231 cells before and
after POU1F1 knockout—were carried out in normal
mammary fibroblasts (NMF) obtained from a normal patient
after mammoplasty, confirming the results obtained with
NAF823 (Supplementary Fig. S7A, B).
POU1F1-induced lactate mediates CAF activation
To evaluate the effect of lactate on NAF to CAF activation,
NAF823 and NMF were treated for 24 h with 20 mM lac-
tate, and α-SMA protein levels were evaluated by western
blot (Supplementary Fig. S8A). Both NAF823 and NMF
showed a significant increase in α-SMA after lactate treat-
ment with respect to untreated control fibroblasts (Fig. 7G,
H). In fact, to correlate our in vitro data with clinical out-
come, LDHA/α-SMA mRNA levels were analyzed in a
breast cancer patient database (n= 3951) (http://kmplot.
com). A significant (P < 0.001) correlation was found
between LDHA/α-SMA and RFS (Fig. 7I). To analyze the
effect of POU1F1 and lactate at protein level on CAF
activation, CM was collected from a 24-h culture of stable
MCF7-POU1F1 cells (control) treated either with 10 μM of
an LDHA inhibitor (MCF7-POU1F1-LDHAi) or after
LDHA knockdown (MCF7-POU1F1-shLDHA, see Sup-
plementary Fig. S4C). Then, NAF823 and NMF were
treated for 24 h with CM (Supplementary Fig. S8B, C), and
α-SMA was immunoblotted to evaluate protein expression.
The results were similar to those obtained after treatment
with 20 mM lactate (Supplementary Fig. S8D–G).
Discussion
The current study demonstrates that the POU1F1 tran-
scription factor induces metabolic reprogramming by
enhancing aerobic glycolysis of human breast cancer cells
through transcriptional regulation of the LDHA gene (Fig.
7J). Elevated expression of LDHA increases conversion of
pyruvate to lactate. In turn, the LDHA-dependent lactate
increases proliferation of hypoxic cancer cells as well as
migration and invasion. In addition, cancer cell-secreted
lactate modifies fibroblast phenotype, which activates the
conversion of NAF into CAF. LDHA downregulation in
tumors of mice with POU1F1 overexpression significantly
reduces tumor growth and tumor [18F]FDG uptake. In
summary, our data revealed POU1F1 as a new factor of
glycolysis regulation and demonstrate an important role for
lactate in both cancer cells and fibroblasts to mediate cancer
progression. Both POU1F1/LDHA and POU1F1/α-SMA
expression correlate with clinical outcome, suggesting
POU1F1 as a prognostic factor in breast cancer.
High POU1F1 expression in breast cancer cells is related
to high cell proliferation, migration, invasion, and low
apoptotic rate [22]. These features together with induction
of EMT indicate that POU1F1 induces breast cancer pro-
gression [22]. In the present study, our first objective was to
evaluate possible metabolic changes in breast cancer
mediated by POU1F1. Increased glucose uptake relative to
the surrounding normal tissues has emerged as a hallmark
Fig. 5 LDHA knockdown in POU1F-overexpressing cancer cells
reduces tumor growth, and tumor glucose uptake in vivo. A Body
weight of mice orthotopically injected with MCF7, MCF7-POU1F1,
and MCF7-POU1F1-shLDHA human breast cancer cells (n= 7 mice
per group). B Tumor volume of mice injected with MCF7, MCF7-
POU1F1, and MCF7-POU1F1-shLDHA cells and representative
images of tumors. Scale bar: 1000 μm. C qWB analysis of POU1F1,
LDHA and β-actin in tumors from nine mice injected with MCF7 (n=
3), MCF7-POU1F1 (n= 3) and MCF7-POU1F1-shLDHA cells (n=
3). D ki67 immunostaining of mouse tumors. Scale bar: 50 μm. E On
the left, SUVmax values for the three experimental groups (n= 4 mice
per group). Significant differences can be observed between MCF7-
POU1F1 and other groups (*P < 0.05, **P < 0.01). On the right, [18F]
FDG PET/CT images from representative BALB/c-nu mice. Metabolic
activity is coded on a color scale ranging from blue (low [18F]FDG
uptake) to red (high [18F]FDG uptake). At the top, xenograft tumors
indicated by arrows on CT images. At the bottom, tumors delineated
using PET/CT images. Axial views are also shown. F Correlation
between POU1F1 and LDHA mRNA expression and relapse-free
survival (RFS) in human breast tumors (n= 3951). G Correlation
between POU1F1 and LDHA mRNA expression and overall survival
(OS) in human breast tumors (n= 42). Analysis of (F) and (G) were
done using the KM plotter and the ProgGeneV2 online tools,
respectively.
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of cancer metabolism [30]. High glucose metabolism is
accompanied by increased aerobic glycolysis in breast
cancer cells, which produce lactate from pyruvate instead of
transforming pyruvate into Acetyl CoA, as occurs in normal
cells. We found increased glycolysis in breast tumors vs.
normal breast, in Luminal B vs. Luminal A tumors, in
HER2 vs. Luminal A tumors, in TNBC vs. luminal A
tumors, and in metastasis vs. primary breast tumors, cor-
roborating previous reports that glycolysis is related to
aggressiveness in breast tumors [31]. Although it has
recently been reported that the main upregulated pathway in
micrometastasis is OXPHOS [32], we found both OXPHOS
and glycolysis to be a hallmark in metastasis. The avail-
ability of nutrients in metastatic niche is different than in
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primary tumors, and metabolism is not the same in all
metastatic niches. After POU1F1 overexpression, we found
a significant increase in the glycolysis signature. Microarray
data were confirmed by qPCR, showing increased mRNA
expression of multiple enzymes belonging to the glycolysis
pathway, as well as elevated mRNA levels of glucose
GLUT1 and lactate MCT4 transporters in MCF7 cells after
POU1F1 overexpression. MCT4 lactate transporter is a
critical determinant of disease prognosis and glycolytic
metabolism. Targeting MCT4 suppresses tumor growth and
yields vulnerability to metabolic stress [33]. In addition,
high lactate levels are present in CM of MCF7-POU1F1
cells, demonstrating increased aerobic glycolysis and lactate
secretion. Functionally, metabolic analyses in either MCF7
cells with POU1F1 overexpression or MDA-MB-231 cells
after POU1F1 knockout indicate that POU1F1 reprograms
cancer cell metabolism toward a glycolytic pattern. Impor-
tantly, primary cultures of human breast tumors with low
and high POU1F1 expression showed similar metabolic
results to those obtained in cell lines after POU1F1
knockout and overexpression.
The LDHA enzyme is a key component of the glycolysis
pathway. However, only a few factors that transcriptionally
regulate LDHA are currently known. Among them, the c-
Myc oncogenic transcription factor transactivates LDHA
gene and stimulates aerobic glycolysis [34], and the HIF-1α
transcription factor upregulates the rate-limiting enzyme for
glycolysis (GLUT1 transporter) and transcriptionally reg-
ulates LDHA [35, 36]. Our study showed that LDHA
mRNA is highly expressed in tumors with respect to normal
breast and we found a significant correlation between
POU1F1 and LDHA mRNA expression. In fact, two
POU1F1 binding sites were identified in the promoter
region of the LDHA gene, and luciferase reporter assays
demonstrated that POU1F1 transcriptionally regulates the
LDHA gene. Interestingly, we found that the histone mark
H3K27ac, which is related to active enhancer regions, is
increased in TNBC as compared with luminal breast cancer
cell lines. This suggests an increased transcriptional activity
of POU1F1 and consequently increased expression of
LDHA in highly aggressive breast cancer cell lines [37]. At
functional level, the upregulation of LDHA by POU1F1
interferes with mitochondrial respiration, turning cancer cell
metabolism into aerobic glycolysis instead of OXPHOS.
Furthermore, pharmacological and genetic LDHA blockade
reduces cell migration and invasion and, interestingly,
decreases breast cancer cell proliferation under hypoxic
environment. Because POU1F1 does not modify HIF-1α
expression (data not shown), our data suggest that POU1F1
regulates LDHA in hypoxic cells independently of HIF-1α.
Our results are in line with those previously obtained by
Leder’s group, who demonstrated that LDHA knockdown
resulted in a compromised ability of tumor cells to pro-
liferate under hypoxia [7]. In vivo, LDHA knockdown in
POU1F1-overexpressing tumors reduces cell proliferation
and tumor growth, and, importantly, decreases [18F]FDG
uptake. In fact, [18F]FDG PET/CT imaging is widely used
in clinical practice for staging and follow-up after cancer
treatment.
In addition to its role in breast tumors, POU1F1-
mediated glycolytic activity could also have important
physiological and pathological consequences. POU1F1
plays a key role in cell differentiation during anterior
pituitary gland organogenesis in mammals [38], and the
POU family of transcription factors (POU1F1, Oct, and
Unc) are critical in key biological processes, such as cell
proliferation, determination of cell lineage fate and reg-
ulation of cell migration, survival, and terminal differ-
entiation [39]. Furthermore, as commented above,
increased LDHA-mediated glycolysis is related to invasion
and proliferation of pituitary adenomas [17]. Given that
POU1F1 is mainly expressed in the pituitary gland, we
could speculate that POU1F1-LDHA-mediated glycolysis
plays a role in pituitary cell differentiation and proliferation.
TME consisting of tumor cells and host stromal cells has
emerged as an important player in tumor progression.
Among stromal cells, macrophages and fibroblasts are the
major components of tumor mass. Recently, we have
demonstrated that POU1F1 overexpression induces both
recruitment of monocytes-macrophages to breast tumor area
and polarization of macrophages into TAM [40]. In the
present study, we evaluated the role of POU1F1 in fibro-
blast activation. CAFs are central elements of the TME,
interacting with tumor cells and other stromal cells [41].
Fig. 6 POU1F1 expression correlates with stromal activation in
breast cancer tumor samples. A–C POU1F1 and ACTA2 mRNA
expression in 21 breast tumor samples were evaluated by qPCR and
plotted by POU1F1 expression (high POU1F1: higher than 75th per-
centile, low POU1F1: below 25th percentile). Dispersion plot indicates
a significant positive correlation between POU1F1 and ACTA2
mRNA. **P < 0.01. D Quantitative western blot (qWB) of POU1F1,
α-SMA, and β-actin (as loading control) in seven patient-derived
breast tumors (PDT 1–7). E Representative immunostaining of
POU1F1 in tumor cells and α-SMA in fibroblasts in human breast
invasive ductal carcinomas with high POU1F1 expression. Scale bar:
75 μm. F Representative immunostaining of POU1F1 in tumor cells
and α-SMA in fibroblasts in human breast invasive ductal carcinomas
with low POU1F1 expression. Scale bar: 75 μm. G Dispersion plot
indicates a significant correlation between POU1F1/β-actin and α-
SMA /β-actin protein levels in seven patient-derived breast tumors. H
POU1F1 and ACTA2 mRNA expression significantly correlate with
relapse-free survival (RFS) in human breast tumor samples (n= 3951)
(http://kmplot.com). I–N Characterization of normal-associated fibro-
blasts (NAFs, in the breast tumor surrounding tissue) and cancer-
associated fibroblasts (CAFs, in the breast tumor tissue) in three
human breast tumor samples based on ACTA2 mRNA and α-SMA
protein expression measured by qPCR and qWB. Data are expressed
as mean ± SEM from three independent Western blots. **P < 0.01,
***P < 0.001.
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Although CAFs may have tumor suppressive properties,
they mainly have tumor promoting capacities. In fact, high
CAF presence in TME is related to cancer prognosis and
response to therapy [42]. Our study demonstrates a clear
relationship between POU1F1 and α-SMA in breast tumors
as well as the clinical prognostic value of both POU1F1 and
ACTA2 mRNA expression. In addition, POU1F1-derived
lactate induces NAF into CAF activation, which is partially
reverted by either POU1F1 knockdown or LDHA blockade.
In some tumors, lactate has recently been reported to epi-
genetically reprogram mesenchymal stem cells to differ-
entiate into CAFs, thus leading to tumor progression [15]. In
addition, lactate binds to the GPR81 lactate receptor, which
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cells [43, 44]. GPR81 is also expressed in stromal cells, such
as antigen presenting dendritic cells, suggesting that tumoral
lactate prevents dendritic stromal cells from presenting
cancer cell-specific antigens to other immune cells, which
may be of importance to cancer cell immune evasion [45].
The present study evaluated neither epigenetic reprogram-
ming of NAFs through POU1F1-induced lactate nor GPR81
lactate receptors in NAFs, but we cannot exclude either
possibility in lactate-mediated NAF to CAF activation.
Altogether, our data suggest that LDHA and POU1F1
could be important therapeutic targets in cancer. Interest-
ingly, Sherman et al. [46] have demonstrated that pancreatic
stellate cells, the predominant fibroblastic cell type in the
TME of pancreas tumors, are reconverted to quiescent state
by stromal remodeling after vitamin D treatment, indicating
a molecular strategy to transcriptional reprogramming of
tumor stroma. POU1F1 is transcriptionally repressed by
vitamin D and its analogs [47, 48]. This led us to hypo-
thesize that vitamin D treatment alone and/or in combina-
tion with LDHA inhibitors [49] might be a therapeutic
strategy in breast cancer, acting on both cancer and stromal
cells to potentiate the chemotherapeutic response in breast
tumors. The effect of both treatments in glycolytic breast
tumors should be further elucidated.
Material and methods
Cell culture, reagents, and CM
The human breast adenocarcinoma MCF7 and MDA-MB-
231 cell lines were obtained from the European Collection
of Cell Culture (ECACC; Porton Down, UK). MCF7 Tet-
Off cells were purchased from Clontech-Takara (Kusatsu,
Japan). All cells were negative and periodically tested for
mycoplasm. Cell lines were cultured in DMEM supple-
mented with 10% FBS (Gibco, Paisley, UK) and grown in
an air-CO2 (95:5) atmosphere at 37 °C. Hypoxic experi-
ments were carried out at 1% O2. The LDHA inhibitor used
at 10 μM in all experiments was purchased from Tocris
(GSK 2837808 A, Minneapolis, USA). Lactate (Sigma-
Aldrich, San Luis, USA) was used at 20 mM. CM was
obtained after seeding the cells at 2 × 105 cs/cm2 in DMEM
with 10% FBS and cultured overnight. Afterward, cells
were washed in PBS and cultured again in DMEM/F12
without FBS for 24 h. Medium was centrifuged for 5 min at
300 g and the supernatant was collected and used immedi-
ately or stored at −80 °C.
Details of additional methodology can be found in
Supplementary Data.
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